Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings results on February 24, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $0.57, missing the consensus estimate of $0.98 by $0.41 per share. Revenue came in at $243.8M, beating the estimate of $241.5M.
Harmony Biosciences's stock moved following the earnings release. The stock currently trades at $27.95 with a market capitalization of $2.3B.